Understanding primary and adaptive tumour immune
resistance The Biomedical Melanoma Research Group at the Vall
d'Hebron Research Institute (VHIR), Barcelona, invites expressions
of interest from outstanding postdoctoral researchers interested in
developing competitive applications for the next Marie
Sklodowska-Curie Postdoctoral Fellowships (MSCA-PF) and/or AECC
Talent postdoctoral calls. Marie Skłodowska-Curie Actions –
Postdoctoral Fellowships (MSCA-PF) The Marie Skłodowska-Curie
Postdoctoral Fellowships (MSCA-PF) are part of the Horizon Europe
programme and support postdoctoral researchers in developing an
original research and innovation project through international
mobility. The programme aims to strengthen researchers’ careers
through excellent science, international collaboration and
interdisciplinary experience, while fostering integration in both
academic and non-academic environments. The MSCA-PF call is highly
competitive and represents an excellent opportunity to attract
international talent and support researchers in consolidating their
scientific careers through an ambitious mobility-based fellowship.
The 2026 call closes on 09/09/2026 (17:00 Brussels time). For
candidates applying to a European Postdoctoral Fellowship, the
fellowship duration is from 12 to 24 months . Full eligibility
details: MSCA Postdoctoral Fellowships 2026 Background Cancer
immunotherapy has reshaped the treatment landscape for multiple
cancers, offering long-lasting clinical benefit to some patients.
However, a large proportion of tumours remain unresponsive or
eventually acquire resistance, revealing a major gap in our
understanding of how cancer cells communicate with and manipulate
the immune system. Increasing evidence suggests that
stress-signalling pathways within tumour cells can profoundly
influence immune surveillance, inflammation, and the composition of
the tumour microenvironment. In this context, p38α emerges as a
compelling molecular hub linking tumour adaptation,